.
MergerLinks Header Logo

Announced

Completed

Huma Therapeutics completed the acquisition of Alcedis.

Financials

Edit Data
Transaction Value-
Consideration TypeCash
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Germany

Completed

Majority

Cross Border

Single Bidder

Friendly

Acquisition

research company

Test Inspection and Certification (TIC)

Private

Synopsis

Edit

Huma Therapeutics, a digital health company, completed the acquisition of Alcedis, a clinical research and technology. Financial terms were not disclosed. "We are excited to be joining the Huma family, bringing our clinical trials expertise and capabilities to combine with those of Huma's award-winning technology-platform. Together, we will offer substantially greater benefit to pharmaceutical, medtech, clinical research organisation, and academic partners for their research projects," Hanno Härtlein, Alcedis Managing Director.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US